Vertex Pharmaceuticals (VRTX) Stock Forecast & Price Target

$483.00

-15.73 (-3.15%)

(As of 10/18/2024 ET)

Vertex Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Hold

Based on 29 Analyst Ratings

Sell
3

Hold
9

Buy
17

Based on 29 Wall Street analysts who have issued ratings for Vertex Pharmaceuticals in the last 12 months, the stock has a consensus rating of "Hold." Out of the 29 analysts, 3 have given a sell rating, 9 have given a hold rating, and 17 have given a buy rating for VRTX.

Consensus Price Target

$492.92
2.05% Upside

According to the 29 analysts' twelve-month price targets for Vertex Pharmaceuticals, the average price target is $492.92. The highest price target for VRTX is $600.00, while the lowest price target for VRTX is $325.00. The average price target represents a forecasted upside of 2.05% from the current price of $483.00.

VRTX Analyst Ratings Over Time

Type	Current Forecast 10/21/23 to 10/20/24	1 Month Ago 9/21/23 to 9/20/24	3 Months Ago 7/23/23 to 7/22/24	1 Year Ago 10/21/22 to 10/21/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	17 Buy rating(s)	16 Buy rating(s)	16 Buy rating(s)	13 Buy rating(s)
Hold	9 Hold rating(s)	7 Hold rating(s)	6 Hold rating(s)	6 Hold rating(s)
Sell	3 Sell rating(s)	3 Sell rating(s)	3 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$492.92	$486.36	$458.50	$367.50
Forecasted Upside	2.05% Upside	4.61% Upside	-7.54% Downside	1.56% Upside
Consensus Rating	Hold	Moderate Buy	Moderate Buy	Moderate Buy

This Bull Market Indicator called NVDA at $116 (Ad)

Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…

All you have to do is follow this link here

VRTX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

VRTX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Vertex Pharmaceuticals Stock vs. The Competition

Type	Vertex Pharmaceuticals	Medical Companies	S&P 500
Consensus Rating Score	2.48	2.79	2.50
Consensus Rating	Hold	Moderate Buy	Hold
Predicted Upside	2.05% Upside	13,587.63% Upside	6.20% Upside
News Sentiment Rating	Positive News See Recent VRTX News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
10/17/2024	UBS Group 4 of 5 stars	C. Bristow Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$477.00 ➝ $562.00	+13.15%
10/16/2024	Scotiabank 5 of 5 stars	G. Harrison Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sector Perform	$480.00	-0.89%
10/14/2024	Bank of America 4 of 5 stars		Lower Target	Buy ➝ Buy	$550.00 ➝ $541.00	+12.03%
10/10/2024	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Brill Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform
10/8/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Overweight	$480.00 ➝ $480.00	+5.46%
10/4/2024	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Sector Perform ➝ Sector Perform	$431.00 ➝ $425.00	-6.68%
Man behind OpenAI makes shocking new bet (Ad) Billionaire Sam Altman has become one of the most powerful men in the world by running OpenAI… But there’s a far lesser known investment he’s making that could put OpenAI to shame. In fact this Sam Altman-backed company could actually become a crucial partner for OpenAI… And the US Military… not to mention hundreds of other giant companies around the globe. To make the story even crazier… this company only recently became viable, thanks to an obscure piece of legislation that President Trump signed before he left office… Which ordered the government to take this incredible new technology seriously. Check out our report right here.
10/1/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Equal Weight ➝ Equal Weight	$462.00 ➝ $474.00	+1.92%
8/5/2024	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$500.00 ➝ $600.00	+25.81%
8/5/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$500.00 ➝ $550.00	+15.31%
8/5/2024	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$508.00 ➝ $550.00	+16.17%
8/5/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$505.00 ➝ $510.00	+7.72%
8/5/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	G. Wang Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Equal Weight	$472.00 ➝ $509.00	+2.94%
8/2/2024	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$450.00 ➝ $558.00	+13.08%
8/2/2024	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$500.00 ➝ $535.00	+7.40%
7/31/2024	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Sell ➝ Sell	$371.00 ➝ $376.00	-25.90%
7/26/2024	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Hold
7/23/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$450.00 ➝ $500.00	+1.60%
6/27/2024	Redburn Atlantic Subscribe to MarketBeat All Access for the recommendation accuracy rating	S. Chesney Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$545.00	+14.98%
6/24/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$540.00 ➝ $555.00	+18.41%
6/17/2024	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$465.00 ➝ $550.00	+15.48%
5/31/2024	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$480.00 ➝ $500.00	+11.63%
4/11/2024	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	In-Line ➝ Outperform	$438.00	+10.17%
2/15/2024	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$515.00	+23.24%
2/6/2024	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform
2/2/2024	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Market Perform
1/31/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Neutral ➝ Underperform	$325.00	-25.27%
1/31/2024	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold
11/22/2023	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Hold ➝ Hold	$373.00	+5.81%
6/26/2023	888 Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Reiterates
5/25/2023	Westpark Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Hold
2/8/2023	SVB Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$374.00 ➝ $365.00	+18.30%
2/8/2023	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform	$374.00 ➝ $365.00	+18.30%
12/19/2022	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold	$340.00	+11.55%
10/28/2022	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$315.00 ➝ $330.00	+10.34%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 12:38 AM ET.

Should I Buy Vertex Pharmaceuticals Stock? VRTX Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Thursday, October 10, 2024. Please send any questions or comments about these Vertex Pharmaceuticals pros and cons to contact@marketbeat.com.

Vertex Pharmaceuticals
Bull Case

Here are some ways that investors could benefit from investing in Vertex Pharmaceuticals Incorporated:

Vertex Pharmaceuticals stock has shown resilience, trading at $462.99 on October 10, 2024, with a market cap of $119.48 billion, indicating stability and potential growth.
Vertex Pharmaceuticals has a strong portfolio of therapies for treating cystic fibrosis, a chronic genetic disorder, which provides a steady revenue stream and growth potential.
Institutional investors and hedge funds own a significant portion (90.96%) of Vertex Pharmaceuticals stock, indicating confidence in the company's future performance.
Recent insider selling activities may indicate profit-taking but do not necessarily reflect negatively on the company's long-term prospects, providing an opportunity for new investors.
Positive analyst ratings and target prices from reputable firms like Oppenheimer, Wells Fargo, and JPMorgan Chase & Co. suggest a favorable outlook for Vertex Pharmaceuticals stock.

Vertex Pharmaceuticals
Bear Case

Investors should be bearish about investing in Vertex Pharmaceuticals Incorporated for these reasons:

Despite positive analyst ratings, some firms have issued sell ratings on Vertex Pharmaceuticals stock, indicating differing opinions on the company's future performance.
Insiders have been actively selling company stock in recent months, which could raise concerns about their confidence in the company's growth potential or future prospects.
While Vertex Pharmaceuticals has a strong focus on cystic fibrosis treatments, any setbacks in research and development or regulatory approvals could impact the company's revenue and stock performance.
The stock's PE ratio of 29.97 may be considered high by some investors, suggesting that the stock may be overvalued based on its earnings, potentially leading to a correction in the future.
Vertex Pharmaceuticals' stock price volatility, with a beta of 0.40, indicates sensitivity to market fluctuations, which could pose risks for investors seeking stable returns.

VRTX Forecast - Frequently Asked Questions

: According to the research reports of 29 Wall Street equities research analysts, the average twelve-month stock price forecast for Vertex Pharmaceuticals is $492.92, with a high forecast of $600.00 and a low forecast of $325.00.
: 29 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vertex Pharmaceuticals in the last year. There are currently 3 sell ratings, 9 hold ratings and 17 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" VRTX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in VRTX, but not buy additional shares or sell existing shares.
: According to analysts, Vertex Pharmaceuticals's stock has a predicted upside of 2.05% based on their 12-month stock forecasts.
: Over the previous 90 days, Vertex Pharmaceuticals's stock had 1 downgrade by analysts.
: Vertex Pharmaceuticals has been rated by research analysts at Bank of America, Barclays, Canaccord Genuity Group, Cantor Fitzgerald, Guggenheim, HC Wainwright, JPMorgan Chase & Co., Morgan Stanley, Needham & Company LLC, Oppenheimer, Piper Sandler, Raymond James, Royal Bank of Canada, Scotiabank, TD Cowen, Truist Financial, and UBS Group in the past 90 days.
: Analysts like Vertex Pharmaceuticals less than other "medical" companies. The consensus rating for Vertex Pharmaceuticals is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how VRTX compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

$5k to $1.3m in just 3 trades (Ad)

It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.

This page (NASDAQ:VRTX) was last updated on 10/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

Get Started with MarketBeat

	Read Your Daily Newsletter
	Check Out My MarketBeat
	Watch Our Tutorial Videos
	Add a Stock to Your Watchlist
	Set Up an Instant Alert
	View a Company's Profile Page
	View Our Financial Calendars
	View Today's Analyst Ratings

Vertex Pharmaceuticals (VRTX) Stock Forecast & Price Target